EyePoint, Inc.EYPT财报
Nasdaq · 医疗保健 · 实验室分析仪器
EyePoint制药公司总部位于马萨诸塞州沃特敦，是一家专注于将微机电系统（MEMS）与纳米技术应用于给药领域的专业医药企业，依托前沿交叉技术开发创新给药方案，聚焦眼科等领域的药物递送技术创新与产品开发。
主要股东
| 股东 | 持股比例 | 股数 | 变动 | 截至 |
|---|---|---|---|---|
| Cormorant Global Healthcare Master Fund, LP | 12.36% | 6.0M | — | 2023-12-14 |
| Cormorant Asset Management, LP | 12.20% | 8.3M | — | 2024-11-14 |
| Franklin Resources, Inc. | 9.50% | 4.6M | ▼ -2.30pp | 2024-02-06 |
| Adage Capital Partners, L.P. | 9.15% | 4.5M | — | 2024-02-07 |
| BlackRock, Inc. | 7.80% | 4.2M | 无变化 | 2024-11-08 |
| Adage Capital Management, L.P. | 7.08% | 3.8M | ▼ -2.82pp | 2024-11-12 |
| The Vanguard Group | 5.69% | 3.0M | 无变化 | 2024-11-12 |
| Nos. of above persons | 5.44% | 3.7M | ▼ -0.66pp | 2024-11-06 |
| TCG Crossover GP II, LLC | 5.20% | 3.6M | — | 2024-11-07 |
| S.S. OR | 4.80% | 2.2M | — | 2023-12-08 |
| T. ROWE PRICE ASSOCIATES, INC. | 4.70% | 2.5M | ▼ -0.90pp | 2024-11-14 |
内部人交易
Net 90d: −$97.0K · buys $1.03M / sells $1.12M时间范围:
类型:
身份:
| 内部人 | 身份 | 类型 | ||||
|---|---|---|---|---|---|---|
| 2026-04-17 | Ramiro Ribeiro | Chief Medical Officer | Option exercise | 2.4K | $8.26 | $20.1K |
| 2026-04-17 | Ramiro Ribeiro | Chief Medical Officer | Sell (open market) | 2.4K | $15.00 | $36.6K |
| 2026-03-23 | Duker Jay S. | President and CEO | Other | 76.8K | $13.11 | $1.01M |
| 2026-03-23 | Duker Jay S. | President and CEO | Other | 76.8K | $13.11 | $1.01M |
| 2026-03-16 | Duker Jay S. | President and CEO | Buy (open market) | 1.5K | $13.15 | $19.7K |
| 2026-03-04 | Ramiro Ribeiro | Chief Medical Officer | Option exercise | 2.4K | $8.26 | $20.1K |
| 2026-03-04 | Ramiro Ribeiro | Chief Medical Officer | Sell (open market) | 2.4K | $17.87 | $43.6K |
| 2026-03-02 | George Elston | Chief Financial Officer | Gift | 5.0K | $0.00 | $0 |
| 2026-03-02 | George Elston | Chief Financial Officer | Gift | 5.0K | $0.00 | $0 |
| 2026-02-17 | Ramiro Ribeiro | Chief Medical Officer | Option exercise | 2.4K | $8.26 | $20.1K |
1–10 of 11
第 1 页 / 共 2 页